<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825576</url>
  </required_header>
  <id_info>
    <org_study_id>MSD-IIS-54809</org_study_id>
    <nct_id>NCT02825576</nct_id>
  </id_info>
  <brief_title>Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine</brief_title>
  <acronym>P-PERSON</acronym>
  <official_title>Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Sydney Anaesthesia Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Sydney and Central Coast Area Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Sydney Anaesthesia Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of sugammadex (compared with&#xD;
      neostigmine) reduces the rate of postoperative pulmonary complications (PPCs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a local, multi-centre, prospective, randomised, double blinded trial of 976 patients.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The primary objective is to determine if the use of sugammadex (compared with neostigmine)&#xD;
      reduces the rate of postoperative pulmonary complications (PPCs). Secondary objectives are to&#xD;
      determine if the use of sugammadex compared with traditional reversal agents improves patient&#xD;
      quality of recovery, reduces the rate of postoperative nausea and vomiting and reduces the&#xD;
      rate of airway complications in the Post Anaesthesia Care Unit (PACU).&#xD;
&#xD;
      Study procedures:&#xD;
&#xD;
      Following informed consent prior to surgery, patients will be randomised to two groups&#xD;
      allocating drugs used for reversal of muscle relaxation;&#xD;
&#xD;
        1. 2mg/kg sugammadex&#xD;
&#xD;
        2. 50mcg/kg neostigmine with 10mcg/kg glycopyrrolate&#xD;
&#xD;
      Randomisation will be via computer generated numbers, which will be sealed in opaque,&#xD;
      sequentially numbered envelopes.&#xD;
&#xD;
      Treating anaesthetist and staff assessing outcomes will be blinded to treatment.&#xD;
&#xD;
      Patients will have neuromuscular transmission (NMT) monitoring intraoperatively to ensure&#xD;
      return of train-of-four count (TOFC) &gt;2 prior to reversal. Muscle relaxant will be limited to&#xD;
      rocuronium or vecuronium, at the choice of the individual anaesthetist. As this study is&#xD;
      planned to be a 'real world' trial, mode of anaesthesia, analgesia, postoperative nausea and&#xD;
      vomiting (PONV) prophylaxis and time of reversal will be determined by the individual&#xD;
      treating anaesthetist.&#xD;
&#xD;
      Postoperative outcome data will be collected in the recovery unit, on postoperative day 1 and&#xD;
      2 (if still an inpatient), at hospital discharge and via a 30 day post-operative phone call.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      Conservatively estimating the baseline incidence of PPC at 7% baseline incidence and an&#xD;
      equally conservative estimate that sugammadex can reduce this to 3% would produce a&#xD;
      clinically relevant number needed to treat (NNT) of 29. Accepting an alpha error of 0.05 and&#xD;
      beta error of 0.2 would require 930 patients. Allowing for 5% incomplete data and loss to&#xD;
      follow up requires 976 patients.&#xD;
&#xD;
      Groups will be analysed on an intention-to-treat basis&#xD;
&#xD;
        1. PPC rate, QoR-15 score and hospital stay will be assessed as continuous variables&#xD;
&#xD;
        2. Post operative Nausea and Vomiting (PONV) score will be assessed as an ordinal variable&#xD;
&#xD;
        3. Mortality and the presence of respiratory and PACU events will be assessed as&#xD;
           categorical variables.&#xD;
&#xD;
      The effect of sugammadex on continuous variables will be analysed by 2-tailed Student T-test.&#xD;
      The effect of sugammadex on ordinal and categorical variables will be analysed by Chi-squared&#xD;
      tests. Binomial regression analysis will be performed on the categorical outcomes for the&#xD;
      subgroup analyses. Logistic regression will be performed to analyse the effect of PONV risk&#xD;
      on PONV scores.&#xD;
&#xD;
      Appropriate statistical tests to confirm test assumptions are met will be performed. In the&#xD;
      case of non-parametric data, the appropriate test will be performed. Interim analysis is&#xD;
      planned after 50% data completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post operative pulmonary complications.</measure>
    <time_frame>Up to day 2 post operatively.</time_frame>
    <description>Incidence of Postoperative pulmonary complications as defined by The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery Score (QoR-15)</measure>
    <time_frame>Day 1 and Day 30 post operatively</time_frame>
    <description>A 15- item patient-rated post operative questionnaire designed to assess the early postoperative health status of patients after anesthesia and surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post operative nausea and vomiting.</measure>
    <time_frame>Day of surgery.</time_frame>
    <description>Post Operative Nausea and Vomiting (PONV) Score:&#xD;
- no PONV&#xD;
- PONV responsive to antiemetics&#xD;
- PONV unresponsive to antiemetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of airway events in the Post Anaesthesia Care Unit (PACU).</measure>
    <time_frame>Day of surgery.</time_frame>
    <description>Proportion of patient that exhibit one or more of the following PACU Events (recorded by recovery room nursing staff);&#xD;
Any desaturation to oxygen saturation by pulse oximetry (SpO2) &lt;90%&#xD;
Need for manual airway support&#xD;
Need for oropharyngeal or nasopharyngeal airway&#xD;
Need for reintubation in PACU&#xD;
Need for anaesthetist to review the patient&#xD;
Unplanned Intensive Care Unit (ICU) admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 day</time_frame>
    <description>Death of patient within time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">976</enrollment>
  <condition>Pulmonary Complications</condition>
  <arm_group>
    <arm_group_label>Sugammadex group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sugammadex 2mg/kg intravenously at completion of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine/Glycopyrrolate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neostigmine 50mcg/kg plus Glycopyrrolate 10mcg/kg intravenously at completion of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex 2mg/kg given for reversal agent</description>
    <arm_group_label>Sugammadex group</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine/Glycopyrrolate</intervention_name>
    <description>Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent</description>
    <arm_group_label>Neostigmine/Glycopyrrolate group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;18&#xD;
&#xD;
          -  patients presenting for non-cardiac surgery&#xD;
&#xD;
          -  planned operative time of over 1 hour&#xD;
&#xD;
          -  plan to be intubated and to receive muscle relaxants for their surgery&#xD;
&#xD;
          -  plan to stay at least one night in hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous recruitment to the trial&#xD;
&#xD;
          -  Hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Cognitive Impairment, or language proficiency leading to inability to complete QoR-15&#xD;
             questionnaire&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt;40&#xD;
&#xD;
          -  Planned postoperative intubation and ventilation&#xD;
&#xD;
          -  Liver failure with Child-Pugh class B/C&#xD;
&#xD;
          -  Renal failure with either regular peritoneal or haemodialysis or serum creatinine&#xD;
             &gt;140mcgmol/L&#xD;
&#xD;
          -  Women lactating, pregnant or of childbearing potential who are not willing to avoid&#xD;
             pregnancy during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben L Olesnicky, BMBS BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Sydney Anaesthesia Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ben L Olesnicky, BMBS Bsc</last_name>
    <phone>+61 2 9463 2488</phone>
    <email>bolesnicky@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Olesnicky</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Mazo V, Sabaté S, Canet J, Gallart L, de Abreu MG, Belda J, Langeron O, Hoeft A, Pelosi P. Prospective external validation of a predictive score for postoperative pulmonary complications. Anesthesiology. 2014 Aug;121(2):219-31. doi: 10.1097/ALN.0000000000000334.</citation>
    <PMID>24901240</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

